Company: BDRX
Filing Date: 2025-05-01
Form Type: DRS
Source: 0001214659-25-006756
Chunk: 156

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-01
Form: DRS
Chunk 156
---
 goes
against the director.

The Registrant
has entered into a deed of indemnity with each of its directors and officers. Except as prohibited by applicable law, these deeds of indemnity
may require the Registrant, among other things, to indemnify its directors and officers for certain expenses, including attorneys’
fees, judgments, fines and settlement amounts incurred by such directors and officers in any action or proceeding arising out of their
service as a director or officer of the Registrant, or one of its subsidiaries, or arising out of the services provided to another company
or enterprise at the Registrant’s request.

Insofar as indemnification
for liabilities arising under the Securities Act of 1933, as amended, may be permitted to directors, officers or persons controlling us
pursuant to the foregoing provisions, we have been informed that in the opinion of the Securities and Exchange Commission such indemnification
is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

| Item 7. | Recent Sales of Unregistered Securities |

The following information is furnished with
regard to all securities issued by the registrant within the last three years that were not registered under the Securities Act of 1933,
as amended. Unless otherwise indicated below, the issuance of such shares was deemed exempt from registration requirements of the Securities
Act, of 1933, as amended, as such securities were offered and sold outside of the United States to persons who were neither citizens nor
residents of the United States, pursuant to Regulation S, or such sales were exempt from registration under Section 4(2) of Securities
Act of 1933, as amended and Rule 506 of Regulation D promulgated thereunder.

On March 22, 2022, we issued one Ordinary
Share upon the exercise of one warrant issued in February 2019 to a certain institutional investor at an exercise price of £200
per share.

On May 3, 2022,
we issued 1,250 Ordinary Shares to be purchased under the Share Incentive Plan at £0.02 per share to the trust of the Share Incentive
Plan.

On August 3, 2022,
we issued warrants to purchase 16,666 Ordinary Shares to a certain institutional investor at an exercise price of £2.70 per share.

On February 15, 2023, we completed the closing of a private placement pursuant to which we sold to certain institutional investors (1)